Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients. The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 […]

View post to subscribe to site newsletter.

Leyden Labs is developing broad spectrum antivirals that target commonalities of viral families, potentially offering protection against known viruses as well as new viruses as they emerge. The company was founded in 2020 in response to the COVID-19 pandemic by Koenraad Wiedhaup, a former partner at McKinsey & Co, and three previous executives of Crucell, […]

View post to subscribe to site newsletter.

Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Unravel Biosciences has developed a vertically integrated computational platform to discover better drug targets. Instead of classic pharma, which takes a target of interest and develops drugs to bind that specific target, Unravel’s platform screens many drugs in parallel for their real-world impact […]

View post to subscribe to site newsletter.